Clinical trial · Interventional
Analysis of the Resistance and Sensitivity Mechanisms to Teclistamab by Focusing on Single Immune Cell Examination
NCT05945524CI-TRIAL-00088394ResisTecrecruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this study is to discover the immune and oncogenomic features that distinguish patients who respond to teclistamab from patients who are primarily resistant. Moreover, phenotypic and genotypic characteristics that occur with secondary resistance to teclistamab will be analyzed.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Bone marrow sampling | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Analysis of bone marrow
- description
- Analysis of bone marrow in patients initiated treatment by Teclistamab for 18 cycles
- interventionNames
- Other: Bone marrow sampling
Primary outcomes (1)
- measure
- Response to teclistamab at 12 weeks
- timeFrame
- at day 1 Cycle 4 (each cycle is 28 days)
- description
- response according to International Myeloma Working Group criteria
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * With multiple myeloma * Who receive Teclistamab * Consent form signed Exclusion Criteria: * Patient under legal protection
References
Publications (0)
Data not yet available
No reference posted for this study.